Nkarta Ebitda Over Time
| NKTX Stock | USD 2.87 0.12 4.01% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Nkarta Performance and Nkarta Correlation. Nkarta |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nkarta. If investors know Nkarta will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nkarta listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.83) | Return On Assets (0.17) | Return On Equity (0.30) |
The market value of Nkarta Inc is measured differently than its book value, which is the value of Nkarta that is recorded on the company's balance sheet. Investors also form their own opinion of Nkarta's value that differs from its market value or its book value, called intrinsic value, which is Nkarta's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nkarta's market value can be influenced by many factors that don't directly affect Nkarta's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nkarta's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nkarta is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nkarta's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Ebitda Analysis
Compare Nkarta Inc and related stocks such as Monte Rosa Therapeutics, Lyell Immunopharma, and Generation Bio Ebitda Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLUE | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (7.6 M) | (27.5 M) | (70.8 M) | (99.9 M) | (137.1 M) | (130.2 M) |
| LYEL | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (100.8 M) | (207.6 M) | (199.9 M) | (166.7 M) | (226.8 M) | (238.1 M) |
| GBIO | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (36.9 M) | (60.4 M) | (77.7 M) | (114.6 M) | (136.1 M) | (133.3 M) | (140 M) |
| SANA | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (8.2 M) | (139.3 M) | (280.2 M) | (345.8 M) | (256.9 M) | (252.4 M) | (265 M) |
| PASG | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (7.4 M) | (26.9 M) | (112.9 M) | (185.7 M) | (138.4 M) | (98.3 M) | (103.3 M) |
| BDTX | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (4.1 M) | (8.9 M) | (22.9 M) | (66.7 M) | (126.7 M) | (92.3 M) | (86 M) | (90.3 M) |
| ALEC | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (14.9 M) | (32 M) | (56.3 M) | (108.8 M) | (187.9 M) | (29 M) | (129.4 M) | (142.9 M) | (135.7 M) |
| IPSC | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (18.6 M) | (51.4 M) | (89.9 M) | (119.3 M) | (121.2 M) | (127.3 M) |
| KZR | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.8 M) | (8.6 M) | (24 M) | (36 M) | (41.4 M) | (53 M) | (70.1 M) | (99.3 M) | (94.3 M) |
| MLYS | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (18.7 M) | (31.5 M) | (84.7 M) | (80.4 M) |
| RVMD | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (29.8 M) | (39.9 M) | (48.6 M) | (101.9 M) | (179.7 M) | (239.5 M) | (430.6 M) | (409.1 M) |
Nkarta Inc and related stocks such as Monte Rosa Therapeutics, Lyell Immunopharma, and Generation Bio Ebitda description
My Equities
My Current Equities and Potential Positions
| Nkarta Inc | NKTX |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 2.87
Additional Tools for Nkarta Stock Analysis
When running Nkarta's price analysis, check to measure Nkarta's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nkarta is operating at the current time. Most of Nkarta's value examination focuses on studying past and present price action to predict the probability of Nkarta's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nkarta's price. Additionally, you may evaluate how the addition of Nkarta to your portfolios can decrease your overall portfolio volatility.